Mode
Text Size
Log in / Sign up

Meta-analysis finds higher circulating stearic acid associated with lower CKD risk in 18,193 adultsLarge study finds link between specific blood fat and lower kidney disease risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret the association between higher stearic acid and lower CKD risk cautiously as observational evidence.

This meta-analysis examined the association between circulating saturated fatty acids (SFAs) and incident chronic kidney disease (CKD) by pooling data from 13 prospective cohort studies within the Fatty Acids Outcomes Research Consortium. The analysis included 18,193 participants from 9 countries who had baseline estimated glomerular filtration rates (eGFR) greater than 60 mL/min/1.73 m², representing a population with normal kidney function at study entry. The weighted median follow-up across cohorts was 7.6 years, during which 2,554 participants (14.0%) developed incident CKD, defined as an eGFR decline to below 60 mL/min/1.73 m² accompanied by at least a 25% decrease from baseline.

The exposure of interest was circulating concentrations of specific saturated fatty acids measured in different lipid fractions across the included cohorts. Seven cohorts measured SFAs in phospholipids, five measured them in serum or plasma total lipids, and one cohort used cholesterol esters. The analysis focused on five specific SFAs: palmitic acid (16:0), stearic acid (18:0), arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0). The study did not report a specific comparator group but rather examined associations across continuous concentration ranges using interquintile ranges for effect size calculation.

For the primary outcome of incident CKD, the meta-analysis found a statistically significant inverse association with circulating stearic acid (18:0). The relative risk per interquintile range was 0.87 (95% confidence interval: 0.80, 0.95) with a P-value of 0.003, indicating a 13% lower risk of developing CKD with higher stearic acid concentrations. The heterogeneity between studies for this association was low (I² = 14.7%). In contrast, the analysis found no significant associations between incident CKD risk and circulating concentrations of palmitic acid (16:0), arachidic acid (20:0), behenic acid (22:0), or lignoceric acid (24:0). The authors did not report specific effect sizes, confidence intervals, or P-values for these non-significant associations.

The study did not report safety or tolerability findings, as this was an observational analysis of biomarker associations rather than an interventional trial. No adverse event data, serious adverse events, or discontinuation rates were provided. The analysis focused solely on epidemiological associations between circulating biomarkers and clinical outcomes without examining the effects of dietary interventions or pharmacological treatments.

These findings contribute to a growing but inconsistent body of literature on fatty acids and kidney health. Prior studies have yielded mixed results regarding SFA associations with kidney disease, with some suggesting harmful effects of certain SFAs and others showing neutral or potentially protective associations. This meta-analysis provides more precise estimates than individual cohort studies due to its larger sample size and standardized analytical approach across multiple populations. The specificity of the finding to stearic acid rather than SFAs as a class adds nuance to the understanding of how different fatty acid subtypes might relate to kidney function decline.

Several methodological limitations warrant consideration. As an observational meta-analysis, the findings demonstrate association rather than causation. Residual confounding from unmeasured factors such as diet quality, physical activity, or other lifestyle variables could influence the observed associations. The use of different lipid fractions for SFA measurement across cohorts introduces potential measurement heterogeneity, though the consistency of the stearic acid finding across studies suggests robustness. The outcome definition relied solely on eGFR decline without incorporating albuminuria or clinical endpoints like kidney failure, which may limit clinical relevance. The study did not report funding sources or author conflicts of interest, which is important context for interpreting findings.

For clinical practice, these findings suggest that circulating stearic acid concentrations may serve as a biomarker associated with lower CKD risk in adults with normal kidney function. However, clinicians should interpret these results cautiously and avoid making dietary recommendations based solely on this observational evidence. The study does not establish whether modifying stearic acid intake would affect CKD risk, and the biological mechanisms underlying the observed association remain speculative. The finding that only stearic acid showed a significant association—while other SFAs did not—highlights the potential importance of considering specific fatty acid subtypes rather than broad categories in nutritional epidemiology.

Important questions remain unanswered. The biological mechanisms through which stearic acid might influence kidney function decline require investigation through experimental studies. Whether dietary intake of stearic acid-rich foods correlates with circulating concentrations and subsequent CKD risk needs clarification. The generalizability of findings to populations with existing kidney disease, different age groups, or specific comorbidities is unknown. Future research should examine whether these associations persist when using more comprehensive CKD definitions that include albuminuria and clinical endpoints. Intervention studies would be necessary to determine whether modifying stearic acid intake affects kidney disease progression.

This research matters to anyone concerned about kidney health, which affects millions of people worldwide. Chronic kidney disease often develops slowly without symptoms, and finding factors that might influence its development could help with prevention strategies. The study looked specifically at whether certain types of saturated fats circulating in people's blood might be connected to their risk of developing kidney problems over time.

The researchers combined data from 13 different studies across nine countries, involving 18,193 people who started with normal kidney function. They measured various saturated fatty acids in participants' blood samples, then followed people for a weighted median of 7.6 years to see who developed chronic kidney disease. The study defined kidney disease as when the estimated glomerular filtration rate (a measure of kidney filtering ability) dropped below 60 mL/min/1.73 m² and decreased by at least 25% from the starting point.

What they found was interesting but specific. Higher levels of one particular saturated fat called stearic acid (identified as 18:0) were associated with a lower risk of developing kidney disease. For every increase in stearic acid levels across the interquintile range (a statistical measure of spread), the relative risk was 0.87. In simpler terms, this means about a 13% lower risk. Out of all participants, 2,554 developed kidney disease during the follow-up period. The other saturated fats they measured—including palmitic acid, arachidic acid, behenic acid, and lignoceric acid—showed no significant associations with kidney disease risk.

There were no specific safety concerns reported in this analysis since it was an observational study looking at naturally occurring fat levels rather than testing an intervention. The researchers didn't report on adverse events, serious adverse events, or discontinuations because those concepts don't apply to this type of research design.

Several important caveats mean people shouldn't overreact to these findings. First and most importantly, this is an observational study showing association, not causation. Just because higher stearic acid levels were linked to lower kidney disease risk doesn't mean that increasing stearic acid will prevent kidney disease. There could be other factors at play—perhaps people with higher stearic acid levels have different diets, lifestyles, or genetic factors that actually explain the connection. Second, the finding was specific to just one type of saturated fat out of several studied. Third, the outcome was based on laboratory measurements of kidney function, not clinical endpoints like needing dialysis or having kidney failure.

What does this realistically mean for patients right now? This research adds to our understanding of potential factors connected to kidney health, but it doesn't change current medical recommendations. People should not try to increase their stearic acid intake based on this single study. Stearic acid is found in foods like meat, dairy products, and cocoa butter, but changing your diet to include more of these foods could have other health implications that weren't studied here. The findings need to be confirmed by additional research, and scientists need to understand why this association exists before any practical applications could be considered. For now, maintaining kidney health through proven methods—managing blood pressure, controlling blood sugar if you have diabetes, staying hydrated, and avoiding excessive use of certain medications—remains the most sensible approach.

What this means for you:
One blood fat was linked to lower kidney disease risk in a large study, but this doesn't prove it causes protection.

Study Details

Study typeMeta analysis
Sample sizen = 18,193
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Chronic kidney disease (CKD) is a global health problem which is associated with poor outcomes, and its prevalence is expected to increase. Identifying novel risk factors for CKD may lead to improved outcomes. Circulating saturated fatty acids (SFAs) have been posited as contributors to CKD risk. OBJECTIVES: We aimed to evaluate associations between circulating SFAs (measured in phospholipids in 7 cohorts, serum or plasma total in 5 cohorts, and cholesterol esters in 1 cohort) and incident CKD in 13 cohorts, and to pool results by meta-analysis across the studies. METHODS: SFAs were measured in 13 cohorts in the Fatty Acids Outcomes Research Consortium, including 18,193 participants with estimated glomerular filtration rate >60 mL/min/1.73 m across 9 countries. Associations between each SFA [palmitic acid (16:0), stearic acid (18:0), arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0)] and incident CKD (defined as an estimated glomerular filtration rate <60 mL/min/1.73 mand ≥25% decrease from baseline) were assessed by Cox or Poisson regressions. Results were pooled using inverse variance weighted meta-analysis. RESULTS: In total, 2554 participants developed CKD over a weighted median follow-up of 7.6 y. After adjustment, higher concentrations of 18:0 were associated with a lower risk of CKD with minimal heterogeneity (relative risk per interquintile range: 0.87; 95% confidence interval: 0.80, 0.95, P = 0.003, I = 14.7%). These associations remained consistent in secondary and sensitivity analyses. We did not observe significant associations of other SFAs with CKD. CONCLUSIONS: In a meta-analysis of 18,193 participants across 9 countries, we observed no indication that SFA increased CKD risk, whereas higher 18:0 concentrations were associated with a lower risk of CKD. Future research is needed to assess mechanisms by which SFA 18:0 may exert kidney-protective effects, and how circulating SFA 18:0 concentrations may be altered.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.